Connect with us 
The United States has announced a major change in its approach to imported generic medicines. Under the proposed plan, generic drugs will continue to enter the US at a 0% tariff for two years from August 2026. The tariff would then increase to 100% for one year and eventually rise to 200%. The objective is clear: encourage pharmaceutical companies to move more manufacturing to the United States.
However, the plan could also create an unexpected problem for the US healthcare system. Generic medicines are commonly used for everyday treatments, including antibiotics, pain relief, cholesterol, blood pressure and cancer medicines. These products are generally sold at low prices and operate on thin profit margins.
If import costs increase significantly, some manufacturers may raise their prices, reduce supplies or stop selling low-profit medicines in the US. This could affect the availability of affordable medicines and increase the risk of shortages for American patients.
What Is The Current News Article Saying: Build Pharmaceutical Factories in America Within Two Years, or Pay Extremely High Tariffs
This current news article focuses on the American side of Trump’s generic-drug tariff proposal.
The concern is that the tariffs may hurt Indian pharmaceutical exporters, but they could also create a bigger problem for the United States itself: higher medicine prices, fewer suppliers and possible shortages of affordable generic medicines.
Under the announced plan:
| Period | Tariff on imported generics |
| Until August 1, 2028 | 0% |
| August 2028–August 2029 | 100% |
| From August 2029 | 200% |
The objective is to give foreign drug manufacturers two years to establish factories in the US. Companies that continue manufacturing abroad could then face extremely high import duties
Why are generic medicines important?
Generic medicines are affordable versions of branded medicines whose patents have generally expired.
They include common treatments such as:
- Antibiotics;
- Blood-pressure medicines;
- Cholesterol medicines;
- Contraceptive pills;
- Depression treatments;
- Cancer medicines; and
- Everyday painkillers.
More than 90% of prescriptions in the US are filled with generic medicines. Therefore, this is not a small or specialised part of the healthcare system—it is the main source of medicines for millions of Americans.
Are Trump’s tariffs on generic drugs definitely final?
The announcement is significant, but important details remain unclear.
The tariff roadmap was announced through a social-media post. Detailed implementation would normally require formal government and customs instructions covering matters such as:
- Which generic medicines are included;
- Whether APIs and ingredients are included;
- Whether essential medicines will be exempt;
- What level of US investment will qualify for protection;
- Whether existing US facilities will qualify;
- Whether country-specific exemptions will apply; and
- How tariffs will apply to companies partly manufacturing in the US.
The earlier official White House proclamation specifically said that generic pharmaceuticals and their associated ingredients would not be adjusted “at this time.” Therefore, the final legal notification for the newly announced generic-drug tariff will be critical.
Why does India matter?
India is one of the largest suppliers of generic medicines to the US. Indian pharmaceutical exports to America totalled approximately $10.5 billion in 2024–25, according to figures cited from India’s Commerce Ministry.
For some individual medicines, the US is highly dependent on Indian manufacturers. The article reports that around 65% of US contraceptive-pill prescriptions in 2024 were manufactured by two India-based companies: Glenmark and Lupin.
This means replacing Indian supplies cannot always happen immediately. Even when an American company wants to manufacture the same medicine, it needs:
- The required formulation;
- Approved raw-material suppliers;
- An FDA-approved facility;
- Sufficient production capacity; and
- Regulatory approval for the product.
India is one of the world’s most important manufacturing centres for generic medicines. Its established pharmaceutical ecosystem includes manufacturers of finished medicines, active pharmaceutical ingredients, packaging materials, research services, testing facilities and regulatory-support providers.
For international pharmaceutical businesses, the proposed US tariff is a reminder that depending on one manufacturing location or one export market can be risky.
Setting up a company in India would not automatically protect a business from US tariffs. Medicines manufactured in India and exported to the US could still be subject to the proposed duties. However, India can help foreign companies create a more diversified and cost-effective global supply chain.
For example, a foreign pharmaceutical company could use India for:
- Manufacturing medicines for India and other global markets;
- Producing active pharmaceutical ingredients;
- Research and formulation development;
- Quality testing and regulatory support;
- Contract manufacturing; and
- Serving markets across Asia, Africa, Europe and the Middle East.
The company may separately establish or maintain US manufacturing capacity for products specifically intended for American customers.
How Can Mercurius Help?
Setting up a pharmaceutical business in India can involve several steps, from company registration and FDI compliance to tax registrations, import-export approvals and ongoing legal requirements.
Mercurius can help foreign businesses manage these processes in a clear and organised way.
Our team supports you in choosing the right business structure, registering your company and meeting the required compliance obligations, so you can focus on building and growing your operations in India.
https://masllp.com/contact-us/
